These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

633 related items for PubMed ID: 31863604

  • 1. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
    Hall KH, Liu Y, Jiang C, Harvey RD.
    Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y.
    JAMA Oncol; 2019 Mar 01; 5(3):376-383. PubMed ID: 30589930
    [Abstract] [Full Text] [Related]

  • 5. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA.
    Eur J Cancer; 2020 Mar 01; 128():17-26. PubMed ID: 32109847
    [Abstract] [Full Text] [Related]

  • 6. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V, Goldschmidt V, Laparra A, Messayke S, Danlos FX, Romano-Martin P, Champiat S, Voisin AL, Baldini C, Massard C, Laghouati S, Marabelle A, Lambotte O, Michot JM.
    Eur J Cancer; 2021 Nov 01; 158():217-224. PubMed ID: 34627664
    [Abstract] [Full Text] [Related]

  • 7. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies.
    Baldini C, Martin Romano P, Voisin AL, Danlos FX, Champiat S, Laghouati S, Kfoury M, Vincent H, Postel-Vinay S, Varga A, Vuagnat P, Ribrag V, Mezquita L, Besse B, Hollebecque A, Lambotte O, Michot JM, Soria JC, Massard C, Marabelle A.
    Eur J Cancer; 2020 Apr 01; 129():71-79. PubMed ID: 32143106
    [Abstract] [Full Text] [Related]

  • 8. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.
    Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC.
    Int J Rheum Dis; 2019 Feb 01; 22(2):297-302. PubMed ID: 30549256
    [Abstract] [Full Text] [Related]

  • 9. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A, Kottschade L, Ryder M.
    Thyroid; 2020 Feb 01; 30(2):177-184. PubMed ID: 31813343
    [Abstract] [Full Text] [Related]

  • 10. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
    Patrinely JR, Young AC, Quach H, Williams GR, Ye F, Fan R, Horn L, Beckermann KE, Gillaspie EA, Sosman JA, Friedman DL, Moslehi JJ, Johnson DB.
    Eur J Cancer; 2020 Aug 01; 135():211-220. PubMed ID: 32599411
    [Abstract] [Full Text] [Related]

  • 11. Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis.
    Song SJ, Song YK, Jang M, Shin E, Suh SY, Cho YS, Lee JY, Oh JM.
    Target Oncol; 2023 Jan 01; 18(1):147-158. PubMed ID: 36515782
    [Abstract] [Full Text] [Related]

  • 12. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H, Hayashi T, Takigami K, Imaizumi K, Shiroki R, Ohmiya N, Sugiura K, Kawada K, Sawaki A, Maeda K, Ando Y, Uyama I.
    BMC Cancer; 2020 Jul 14; 20(1):656. PubMed ID: 32664888
    [Abstract] [Full Text] [Related]

  • 13. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X.
    BMC Cancer; 2019 Jun 10; 19(1):558. PubMed ID: 31182061
    [Abstract] [Full Text] [Related]

  • 14. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
    Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S.
    Eur J Cancer; 2018 Jun 10; 96():91-104. PubMed ID: 29698933
    [Abstract] [Full Text] [Related]

  • 15. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.
    Shazib MA, Woo SB, Sroussi H, Carvo I, Treister N, Farag A, Schoenfeld J, Haddad R, LeBoeuf N, Villa A.
    Oral Dis; 2020 Mar 10; 26(2):325-333. PubMed ID: 31642136
    [Abstract] [Full Text] [Related]

  • 16. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D.
    J Hepatol; 2018 Jun 10; 68(6):1181-1190. PubMed ID: 29427729
    [Abstract] [Full Text] [Related]

  • 17. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
    Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, Bersanelli M, Lazzarin A, Bordi P, Catino A, Pizzutilo P, Galetta D, Marchetti P, Botticelli A, Scagnoli S, Russano M, Santini D, Torniai M, Berardi R, Ricciuti B, De Giglio A, Chiari R, Russo A, Adamo V, Tudini M, Silva RR, Bolzacchini E, Giordano M, Di Marino P, De Tursi M, Rijavec E, Ghidini M, Vallini I, Stucci LS, Tucci M, Pala L, Conforti F, Queirolo P, Tanda E, Spagnolo F, Cecchi F, Bracarda S, Macrini S, Santoni M, Battelli N, Fargnoli MC, Porzio G, Tuzi A, Suter MB, Ficorella C, Cortellini A.
    Eur J Cancer; 2020 Jul 10; 134():19-28. PubMed ID: 32454395
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
    Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Russano M, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K.
    Clin Lung Cancer; 2020 Nov 10; 21(6):498-508.e2. PubMed ID: 32680806
    [Abstract] [Full Text] [Related]

  • 20. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N.
    BMC Cancer; 2019 Oct 21; 19(1):974. PubMed ID: 31638948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.